Finance

Lists
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
R$ ३३१.९०
+०.६५%
(+२.१५) 1D
सेप्टेम्बर ३०, ११:३१:२५ GMT-३  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Mkt. cap
१.२७ खरब
Avg. vol.
१०.००
Volume
०.००
52-wk high
R$ ३४७.१५
52-wk low
R$ २२१.७२
Shares outstanding
२.०४ अरब
No. of employees
३२ हजार
Mkt. cap
१.२७ खरब
Avg. vol.
१०.००
Volume
०.००
52-wk high
R$ ३४७.१५
52-wk low
R$ २२१.७२
Shares outstanding
२.०४ अरब
No. of employees
३२ हजार
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
४ घण्टा पहिले
Bristol Myers Squibb stock pre-market at EUR 53.12: plus 0.42 percent
Simply Wall Street
Simply Wall Street
·
१२ घण्टा पहिले
Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?
MarketWatch
MarketWatch
·
१४ घण्टा पहिले
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees३२.५ हजार
Founded१८८७
Headquartersन्यू योर्क शहर, न्यू योर्क, संयुक्त राज्य अमेरिका
Sector-
Websitebms.com
Last report
२०२६ जुलाई ३०
Fiscal period
Q2 2026
EPS / Est. (USD)
US$ २.०४ / US$ १.६०
+२७.७४%beat
Revenue / Est. (USD)
१२.९७ अरब / ११.७४ अरब
+१०.५३%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१२.२२ अरब
१२.५० अरब
११.४९ अरब
१२.९७ अरब
Cost of goods sold
३.३१ अरब
३.५१ अरब
३.४१ अरब
३.७१ अरब
Cost of revenue
३.३१ अरब
३.५१ अरब
३.४१ अरब
३.७१ अरब
Research and development expenses
२.४३ अरब
२.५६ अरब
२.२४ अरब
२.५४ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.७९ अरब
२.०९ अरब
१.६१ अरब
१.८२ अरब
Operating expense
५.०५ अरब
५.४७ अरब
४.२८ अरब
४.८० अरब
Total operating expenses
८.३६ अरब
८.९८ अरब
७.६९ अरब
८.५१ अरब
Operating income
३.८६ अरब
३.५२ अरब
३.८० अरब
४.४६ अरब
Other non operating income
५२.९० करोड
५४.४० करोड
१२.५० करोड
१०.६० करोड
EBT including unusual items
३.११ अरब
१.४७ अरब
३.२४ अरब
४.०९ अरब
EBT excluding unusual items
४.०७ अरब
३.८६ अरब
३.६५ अरब
४.३५ अरब
Income tax expense
९१.९० करोड
३८.४० करोड
५६.१० करोड
७७.०० करोड
Effective tax rate
२९.५१%
२६.१२%
१७.३२%
१८.८४%
Other operating expenses
-
-
-
-
Net income
२.२० अरब
१.०९ अरब
२.६८ अरब
३.३२ अरब
Net profit margin
१८.०१%
८.६९%
२३.३०%
२५.५७%
Earnings per share
१.६३
१.२६
१.५८
२.०४
Interest and investment income
१६.१० करोड
१४.८० करोड
१०.४० करोड
१०.१० करोड
Interest expense
-४८.२० करोड
-४३.२० करोड
-४०.६० करोड
-४०.३० करोड
Net interest expenses
-३२.१० करोड
-२८.४० करोड
-३०.२० करोड
-३०.२० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
४.९१ अरब
४.५४ अरब
४.४१ अरब
५.०८ अरब
Gain or loss from assets sale
-९०.०० लाख
-
-३.४० करोड
-१४.२० करोड
AI content may include mistakes. Learn more
Google एपहरू